To engage communities through the power of arts and culture to educate, empower and mobilize individuals toward positive change. Thriving Together Atlanta serves as a model of how cross-sector partnerships can address multifaceted issues affecting communities today.

To help implement the CDC Foundation programs and activities supporting the Targeted Country Assistance portion of the 2022-2025 Partners’ Engagement Framework.

To investigate the biocompatibility, the drug release profile and length of prophylactic efficacy of a biodegradable subcutaneous implant containing antiretroviral drug(s), developed by RTI.

To support the introduction of a change in Burkina Faso’s infant pneumococcal vaccine schedule to include a booster dose and to evaluate the impact of the country’s capacity to control pneumococcal disease among children and adults.

To evaluate the safety, pharmacokinetics and efficacy of macaque-sized CLIP 3D printed intravaginal rings (IVRs) loaded with the potent antiretroviral Islatravir (EFdA) when administered vaginally to pigtailed macaques.

To evaluate the impact of a pneumococcal conjugate vaccine schedule change in Mozambique on vaccine-type pneumococcal carriage and invasive pneumococcal disease; and serotype 1 colonization among patients with suspected pneumonia and serotype 1 disease among children and adults.

To support implementation of a set of recommendations and a roadmap developed in the "Strengthening Public Health and Community Based Organization (CBO)" Interface report.

To provide laboratory support for the analysis of immunogenicity and shedding of new oral Poliovirus vaccines in human clinical trials and related issues for polio endgame.

To improve use of antibiotics in outpatient settings, where most prescribing occurs, by providing antibiotic stewardship resources for state health departments and state Medicaid agencies.

To evaluate the efficacy of injectable pre-exposure prophylaxis (PrEP) in HIV-uninfected populations.

To ensure impact and effectiveness of rotavirus vaccines and sustain vaccine use by policy makers, physicians and parents to increase the speed of adoption of vaccine by other countries in Africa and around the world.

To develop cell culture and small animal models of Nipah virus replication and pathogenesis in a biosafety level (BSL) 4 lab.

To improve mental, behavioral and academic support to students, families and teachers by sharing resources and information about COVID-19.

To support key laboratory systems strengthening interventions for early disease detection, disease monitoring, and laboratory based disease surveillance for priority diseases of public health importance in Lagos, Nigeria.

To increase vaccine confidence and access among those most affected by mpox.

To provide support to CDC, working toward the elimination of healthcare-associated infections in all medical care settings.

To maintain, produce, authenticate and distribute arthropod vectors and associated reagents for the Emerging Infections Resources Program.

To complete the Zika Contraceptive Access Network (Z-CAN) through data collection, evaluation and dissemination.

To build community resilience against weather events by supporting local disaster preparedness programs through community-based organizations in the Midwest, with a focus on rural areas.

To provide project management services to include management of design and performance by CDC of an animal research study involving application of microarray patches (MAPs) containing antiretrovirals for HIV treatment to rhesus macaques.

To optimize interventions and tools to enable the elimination and eradication of prioritized Neglected Tropical Diseases (NTDs) as identified by the London Declaration.

To provide travel support for onsite technical assistance to countries conducting various rotavirus studies.

To conduct an evaluation before and two years after the introduction of the Pneumococcal conjugate vaccine (PCV) to study the direct and indirect impact of PCV introduction on vaccine-type pneumococcal carriage among healthy Indonesian children under five years of age.

To enable veterinary students from across the United States, Canada and the Caribbean to learn more about opportunities in public health for veterinary professionals.

To support the characterization of non-rotavirus viral diarrheal pathogens to inform the body of work that contributes to optimize the efficacy of rotavirus vaccines.

To investigate other novel interventions, such as monoclonal antibodies (MAbs) against malaria. An intervention that could prevent malaria in children for a full 12 months in settings of perennial malaria transmission, such as Kenya, holds potential to reduce malaria morbidity and mortality substantially in this population at risk for severe malaria and death.

To support the chemistry, manufacturing and control (CMC) and preclinical development of an inactivated rotavirus vaccine.

To investigate long-acting PrEP formulations in macaque subjects.

To engage partners and stakeholders on awareness and education for infection associated chronic conditions (IACC).